Principles of radioimmunotherapy for hematologists and oncologists

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 12, 2000, Pages 62-73

  Press, O W ^a   Rasey, J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; YTTRIUM 90;

B CELL LYMPHOMA; CONFERENCE PAPER; CYTOTOXICITY; DNA STRAND BREAKAGE; ELECTRON; GAMMA RADIATION; HEALTH CARE PERSONNEL; HEALTH HAZARD; HEMATOLOGY; INTERSTITIAL FLUID; ONCOLOGY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PHYSICS; RADIOIMMUNOTHERAPY; TUMOR VASCULARIZATION; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELOABLATIVE AGONISTS; NEOPLASMS; OXYGEN; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 0034468310     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. 1DEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
4. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
5. 131I-LYM-1 antibody
6. 131I-LYM-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
7. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
8. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
9. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
10. Follow-up of relapsed B-cell lymphoma patients treated with I-131-labeled anti-CD20 (antibody) and autologous stem cell rescue
11. 131I anti-B1 (anti-CD20) antibody
12. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
13. Iodine I-131-tositumomab therapy for previously untreated follicular lymphoma
14. Multicenter phase III study of iodine-131-tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low grade non-Hodgkin's lymphoma
15. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
16. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
17. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies
18. Retention of B-cell specific monoclonal antibodies by human lymphoma cells
19. Comparative metabolism and retention of iodine-131, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
20. 131I-labeled-LYM-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. A pilot study
21. 213Bi-HuM195 (anti-CD33) in patients with leukemia
22. Optimal therapeutic strategies for radioimmunotherapy
23. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice
24. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier
25. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
26. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
27. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: A biomathematical model
28. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
29. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment
30. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
31. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
32. Conventional and hematopoietic stem cell supported radioimmunotherapy with humanized Y-90-LL2 (Y-90hLL2) anti-CD22 monoclonal antibody in NHL patients who failed high dose therapy
33. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies
34. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
35. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B cell NHL: Report of interim results
36. A phase I/II trial of high dose iodine-131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas
37. Radiation effects in normal tissues
38. Cellular effects of ionizing radiation
39. Radiation dose rate: A factor of importance in radiobiology and radiotherapy
40. Cyclic x-ray responses in mammalian cells in vitro
41. Reduced oxygen enhancement ratio at low doses of ionizing radiation
42. Innovative new therapies for non-Hodgkin's lymphomas